Imidazole derivatives have occupied a unique place in the field of medicinal chemistry. The incorporation of the imidazole nucleus is an important synthetic strategy in drug discovery. The high therapeutic properties of the imidazole related drugs have encouraged the medicinal chemists to synthesize a large number of novel chemotherapeutic agents. This study was designed to show the effects of new compounds derivatives from 2-Imidazolidine thione on the activity of Monoamino oxidase in sera. All compounds were studied demonstrated inhibitory effects on the enzyme activity and these effects are increased with increasing the concentrations of the compounds. The compound 2-(4,5-dihydro-1H-imidazol-2-ylthio)-N'-(2-hydroxy benzylidene) acetohydrazide has the highest ability to inhibit MAO than the other compounds.Kinatic properties of these inhibitors reveal that compound 4 causes mixed type of inhibtion,componds 1,3 act as noncompetitive inhibitor and compound 2 behaves as un-competitive inhibitor.
Introduction
(Monoamino oxidases MAO) (EC 1.4.3.4) are an outer mitochondrial membrane-bound flavoenzymes that catalyzes the oxidation of the neurotransmitters serotonin, dopamine, and norepinephrine [1, 2] . Changes in the activity of this enzyme have been observed in numerous neuropsychiatric disorders, and the employment of MAO inhibitors often produces a therapeutic effect [ 3) . In mammals MAO exists in two forms, MAO A and MAO B, which are encoded by two different genes, that differ in their substrate specificity and sensitivity to inhibitors [2, 4] . Recent studies have demonstrated that a deficiency or low level of expression of this enzyme results in a phenotype of aggressive behavior [5, 6] . Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction (too much or too little MAO activity) is thought to be responsible for a number of neurological disorders. For example, unusually high or low levels of MAOs in the body have been associated with depression, [7] schizophrenia [8, 9] substance abuse, attention deficit disorder, migraines, and irregular sexual maturation. Monoamino oxidase inhibitors are one of the major classes of drug prescribed for the treatment of depression, although they are last-line treatment due to risk of the drug's interaction with diet or other drugs [10] . Excessive levels of catecholamines (epinephrine, norepinephrine, and dopamine) may lead to a hypertensive crisis, and excessive levels of serotonin may lead to serotonin syndrome. Positron emission tomography (PET) research which is a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body has shown that MAO is also heavily depleted by use of tobacco cigarettes [10] . This study included study the effect Imidazole derivatives on (MAO) and these compounds have occupied a unique place in the field of medicinal chemistry. The incorporation of the imidazole nucleus is an important synthetic strategy in drug discovery. The high therapeutic properties of the imidazole related drugs have encouraged the medicinal chemists to synthesize a large number of novel chemotherapeutic agents [11] .
Material and Methods
Monoamino oxidase activity was assayed by (Mcwen and Cohen method 1963) [12] .The principle of the method is the measurement of the benzaldehyde from reaction which is absorbed at wave length 242 nm after extraction by cyclohexan. All solution were mixed and centrifuged for 10 min. Then the absorbance of the supernatant was measured at 242 nm. Enzyme activity were measured through aldehyde formed in 3 hrs. by reading absorbance of test against control at wave length 242 nm by U.V spectrophotometer in the laboratory of biochemistry on February 2010. B-Four compounds that found in Table (1) were prepared by Zainab Muhammad Ali [13) .
The following concentrations (10 -2 ,10 -3 , 10 -4 ,10 -5 ,10 -6 )M of these compounds are prepared by diluting with ethanol. MAO activity is measured in human serum by using the same method in previous paragraph with replace 750 µl of MAO buffer solution with 500 µl MAO buffer +250 µl of inhibitor(four compounds found in Table ( 
Result and Discussion
The organic compounds derivatives that we are used have Imidazole ring .Imidazole ring is a planer five-member heterocyclic ring with 3C and 2N atoms and in ring N is present in 1st and 3rd positions. The imidazole ring is a constituent of several important natural products, including purine, histamine, histidine and nucleic acid. [13] . Many researchers study imidazole derivative compounds properties such as, Gaba M. etal [14] study Novel 5-Substituted -1-(phenylsulphonyl) methyl benzimidazole derivatives, they have synthesized and screened for their antiinflammatory as well as analgesic activity, in other study Hranjec M etal [15] ., showed newly synthesized benzimidazole derivatives exerted pronounced antiproliferative activity. Among a synthesized series of aminothiazolo [3,2-a] benzimidazole derivatives Nacetylaminothiazolo [3,2-a] benzimidazole -2-carbonitrile revealed significant in vitro antiproliferative activity which attributed to its ability to arrest G2/M phase and to induce apoptosis in time dependant manner [16] . One of these compounds derivatives from 2-Imidazolidine thione, in this research we investigate of the effects of four compounds, stated in Table (1) . The effect of the solvent (ethanol) showed a slight inhibitory effect on serum of MAO activity, which was calculated to be 0.5% of original activity. The biochemical tests revealed that all compounds caused (moderate to good) inhibitory effects on the enzyme activity, Table ( 2) the normal value of the enzyme activity ranges between (43-110) µmole/3 min/ml. The relationships between compounds concentrations and the activity of enzyme are shown in Fig.(1) . From these results it is observed that any increase in compounds concentrations causes increases in percentage of inhibition of enzyme. The greater inhibition of each compound is demonstrated at concentration (0.001 M) as Fig.(2) . From this figure it is observed that compound (1) revealed higher percentage of inhibition (85.714%).In contrast compound (2) exhibits lower percentage of inhibition (37.209%) than other compounds.
In this study, we determined the type of inhibition and kinetic parameters (K map, Vmap and Ki) at different concentrations of substrate under the same conditions by using Lineweaver-burk equation and one plotted as shown in Fig.(3) , and Table ( 3). Our results revealed that compounds (1,3) have the same type of inhibition(noncompetitive inhibition) this type of inhibition is recognized by its characteristic effect on Vmax, it occurs when the inhibitor and substrate bind at different sites on enzyme. The non-competitive inhibitor can bind either free enzyme or ES complex, there by preventing the reaction from occurring [17] , while compound (2) exhibit observed from all of previous that the differences in potency of inhibition from compound to another belong to the differences in the nature of groups substituted instead of hydrogen atom in 2-Imidazolidine thione compound .Over the past ten years, efforts have been directed to the design, synthesis and study of new monoamine oxidase inhibitors (MAOIs) for the treatment of various mental and neurological disorders. MAO inhibitors of the new generation are usually characterized by their relatives specificities for the MAO subtypes and in some cases by the reversibility of their actions. Despite considerable progress in understanding the interactions of the two enzyme forms with their preferred substrates and inhibitors, no general rules are yet available for the rational design of potent and selective inhibitors of MAO possibly due to the fact that the mechanism of interaction of the new drugs with MAO isoforms have not been fully characterized. Preferential MAO-A inhibitors have been recognized as therapeutically useful antidepressants while MAO-B inhibitors have been found to be beneficial in the treatment of Parkinson's disease and Alzheimer [18, 19, 20] . Bellik L.etal [21] , reported that the novel MAO-B inhibitor PF9601N, its cytochrome P450-dependent metabolite FA72 and l-deprenyl were studied as potential peroxynitrite (ONOO) scavengers and nitric oxide synthase (NOS) inhibitors both the novel MAO-B inhibitor as well as its metabolite were able to strongly inhibit rat brain neuronal NOS (IC50 of 183 μM and 192 μM, respectively), while l-deprenyl at the highest concentration used (3 mM), caused only a slight decrease of the enzyme activity. All these results suggest that PF9601N could be a promising therapeutic agent in neurodegenerative disorders such as Parkinson's disease. In this context, the development of new molecules able to reduce the oxidative stress, thereby slowing the rate of neuronal degeneration, appears to be necessary. A new series of acetylenic and allenic derivatives of tryptamine synthesized as MAO-B inhibitors (MAOIs) have been described [22, 23] . Among these, N-(2-propynyl) -2-(5-benzyloxy indolyl) methylamine (PF9601N) was shown to have a neuroprotective effect in several experimental models of Parkinson's disease (PD). PF9601N protects nigrostriatal dopamine neurons against MPTP neurotoxicity in C57bl /6 adult mice [24] . and protects rat nigral neuronsafter 6-hydroxydopamine striatal lesion [25) . One of these enzymes that act as MAO is Semicarbazide-sensitive amino oxidase (SSAO) is a common name for a group of enzymes, containing copper and quinoneco factor [26] . and sensitive to semicarbazide, that converts primary amines into the corresponding aldehydes, while releasing ammonia and hydrogen peroxide [27] . is found in a great variety of species from prokaryotes to eukaryotes. In mammals, two forms of the SSAO protein have been identified: a tissuebound form and a soluble plasma form [28] . The tissue-bound SSAO contains a short intracellular domain, a single transmembrane domain, and a long extracellular domain that contains the active site [29] . It has been reported that increases in the levels of plasma and/or membrane-associated SSAO occur in many inflammation-associated diseases, including rheumatoid arthritis inflammatory bowel disease, 2 types of diabetes mellitus, atherosclerosis, and chronic heart failure [30] . The possible involvement of SSAO in the inflammatory processes associated with Alzheimer's disease has also been reported [31] . The in-vitro biological results revealed that compounds 4a,c are highly potent SSAO inhibitors with notable selectivity toward SSAO over monoamine oxidases A and B (MAO-A and MAO-B). The most potent and selective compound, 4a (IC50 ) 2 nM), is an orally active, competitive, and apparently irreversible inhibitor of SSAO that is effective at reducing disease [32] . On other hand Gastagnoli K.etal [33] . found that smokers have lowered brain and blood platelet MAO-A and MAO-B activites compared to nonsmokers and that smokers have a lowered incidence of parkinsons disease because the neuroprotective properties of an MAO inhibitor.2,3,6-trimethyl-1,4-naphthoquinone (TMN) which is present in the tobacco plant and smoke in the 1-methyl -4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) C57BL/ 6mouse model of neurodegeneration. 
